Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6446 studies found for:    MS
Show Display Options
Rank Status Study
1 Completed Therapy Optimization in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
2 Unknown  Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients
Condition: Multiple Sclerosis (MS)
Intervention:
3 Completed A Phase I/II Study of GX15-070MS in Untreated CLL
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: GX15-070MS
4 Enrolling by invitation Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
5 Recruiting Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
Condition: Multiple Sclerosis
Interventions: Drug: Vitamin D;   Drug: Placebo;   Other: Imaging;   Biological: Lumbar puncture;   Biological: Blood sampling;   Biological: Urine samples
6 Completed
Has Results
Oral Cladribine in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Placebo;   Drug: Rebif® new formulation (RNF)
7 Unknown  Is MS14 Helpful in Schizophrenia?
Condition: Schizophrenia
Interventions: Drug: MS14;   Drug: Risperidone
8 Not yet recruiting MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS)
Condition: Multiple Sclerosis
Intervention: Drug: Rebif (IFNβ-1b)
9 Completed Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
Condition: Multiple Sclerosis (MS)
Intervention: Drug: H.P. Acthar Gel (repository corticotropin injection)
10 Not yet recruiting Integrating Caregiver Support Into MS Care
Condition: Multiple Sclerosis
Intervention: Behavioral: Behavioral
11 Unknown  Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
12 Completed Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Drug: colecalciferol
13 Recruiting Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients
Conditions: Multiple Sclerosis;   Systemic Sclerosis
Intervention: Other: Blood sample collection
14 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
15 Unknown  Venous Irregularities, Flow and Perfusion in MS Study
Condition: Venous Irregularities, Flow and Perfusion in MS and Non-MS Participants
Intervention:
16 Enrolling by invitation Impact of Vitamin A on Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Dietary Supplement: vitamin A;   Drug: Drug: placebo
17 Recruiting Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)
Condition: Multiple Sclerosis
Intervention:
18 Completed Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects
Condition: Healthy
Intervention: Drug: BIBR 1048 MS
19 Withdrawn Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment
Condition: MS Patient With Relpasing Remitting Attacks
Intervention: Drug: Dexamethasone soduim phosphate
20 Completed AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
Conditions: Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.